Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 132

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 132
---
ew in
January 2024), has recently been approved by the FDA. However, to the best of our knowledge, Agili-C has not yet been launched for commercialization.

<div align='center'>81</div>

If our product is approved
in the United States, it is highly likely that we will face competition from Vericel. Vericel’s MACI utilizes a cellular procedure
requiring two surgeries; one for the biopsy taking out a piece of health cartilage for cellular expansion, and a second which occurs
approximately 10 - 12 weeks thereafter for reimplantation of the expanded cell population. This procedure costs ~$40,000, with a reported
recovery period of 6 weeks. This is a long, complex procedure especially compared to the ~10 minute procedure for the delivery of GelrinC,
which only involves one surgery.

| (1) | Based on Company’s internal measurements of surgery time.                            |
| (2) | Bryn M, Vannabouathong C, AlBuhairan B, Bhandari M.Cost of matrix-induced autologous 
 chondrocyte implantation in the United States.Arthroscopy. 2021;37(12):3499–3506.e1. |

| (3) | Market Cap as of May 1, 2025. Net revenues of $46.3M for MACI                                                                                                         
 in first quarter of Fiscal Year 2025 (https://investors.vcel.com/news-releases/news-release-details/vericel-reports-first-quarter-2025-financial-results-and-raises). |
| (4) | https://www.smith-nephew.com/en/news/2024/01/10/20240110---sn-completes-acquisition-of-novel-cartilage-regeneration.                                                  |

Research Grants

Grants under the Israeli Encouragement of Industrial and Development Law

Our research and development
efforts have been financed in part through royalty-bearing and non-royalty-bearing grants in an aggregate principal amount of $2.34 million
that we received from the IIA as of June 30, 2025 and December 31, 2024. With respect to the royalty-bearing grants, we are committed
to pay royalties at a rate between 3% and 4.5% on sales proceeds from our products that were developed under IIA programs up to the total
amount of grants received, linked to the U